Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

Values. GS-5734 was also effective against bat CoVs, prepandemic bat CoVs, and circulating contemporary human CoV in primary human lung cells, thus demonstrating broad-spectrum anti-CoV activity. In a mouse model of SARS-CoV pathogenesis, prophylactic and early therapeutic administration of GS-5734 significantly reduced lung viral load and improved clinical signs of disease as well as respiratory function. These data provide substantive evidence that GS-5734 may prove effective against endemic MERS-CoV in the Middle East, circulating human CoV, and, possibly most importantly, emerging CoV of the future.

• CF
  Cystic Fibrosis Foundation

  Awards: BOUCHE15RO, award306706
• GS
  Gilead Sciences

  Award: award313646
• NH
  National Heart, Lung, and Blood Institute

  Awards: award306707, P30DK065988
• NI
  National Institute of Allergy and Infectious Diseases

  Awards: 5U19AI109680, award313260, award306704, AI109761, AI108197, award306705